Specialty pharmacy benefit — both Ionis products are self-injected, specialty-only
Blue Plan Consortium · PBM: Prime Therapeutics · National
Prime Therapeutics
PBM-level template drives downstream Blue plans; template update expected next quarter.
Live from the coverage database
Policy Posture and UM Criteria by Indication
No published payer policy has been recorded here yet. Submit field intelligence to start the record.
Coverage Update YTD
Treated Lives — Tryngolza (FCS)
Ionis Brands Published
Pending Policy Changes
Months since launch · illustrative
Treated Lives on Therapy — Tryngolza (FCS)
50-state distribution · illustrative
Treated Lives by State — Tryngolza (FCS)
Tryngolza — FCS Coverage Source Summary
PBM-level template not yet issued for FCS; downstream Blue plans are awaiting the next template refresh.
Historical coverage trend
Tryngolza — FCS Lives Coverage Trend
% of lives by access status across historical snapshots.
Covered
Preferred
Not covered
Unknown
Latest source details
Tryngolza — FCS Coverage Details
3 source views
| Source | Payment Type | Policy Status | Latest Detail |
|---|---|---|---|
| MMIT Searchlight | Commercial | Published — Restricted | Syndicated data reflects the most recent policy language for this indication. |
| FRM submission | Medicare | Limited visibility | Field team confirms account-level nuance not yet captured in syndicated sources. |
| Market Access submission | Medicaid | Limited visibility | State/plan-level detail requires validation against current directories. |
Brand-specific feed
Latest Updates
MMIT Searchlight
Latest source refresh confirms no material change to published criteria this cycle.
FRM submission
Field notes on account-level access nuance submitted for validation.
Brand documents
Shared Documents
PDF, DOC, PNG or JPG · max 20 MB
Policy PDF
Uploaded by Market Access Team
Latest updated: Jun 1, 2026